ES2536438T3 - Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón - Google Patents
Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón Download PDFInfo
- Publication number
- ES2536438T3 ES2536438T3 ES12165748.0T ES12165748T ES2536438T3 ES 2536438 T3 ES2536438 T3 ES 2536438T3 ES 12165748 T ES12165748 T ES 12165748T ES 2536438 T3 ES2536438 T3 ES 2536438T3
- Authority
- ES
- Spain
- Prior art keywords
- mir
- level
- lung cancer
- prognosis
- mir gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método para determinar el pronóstico de un sujeto con cáncer de pulmón, que comprende la medición del nivel de productos génicos de miR en una muestra de ensayo de dicho sujeto, en el que: la firma de los productos génicos de miR está asociada con un pronóstico adverso en cáncer de pulmón; y una alteración del nivel de los productos génicos de miR en la muestra de ensayo de pulmón, con respecto al nivel de los productos génicos correspondientes de miR en una muestra de control, es indicativa de un pronóstico adverso, en donde el cáncer de pulmón es un adenocarcinoma de pulmón, y los productos génicos de miR consisten en miR-155 y let-7a-2; y en donde el nivel del producto génico de miR-155 en la muestra de ensayo es mayor que el nivel del producto génico correspondiente de miR en la muestra de control, y en donde el nivel del producto génico de let-7a-2 en la muestra de ensayo es menor que el nivel del producto génico correspondiente de miR en la muestra de control.
Description
E12165748
07-05-2015
Las Tablas 1a y 1b describen las secuencias de nucleótidos de microARN humanos precursores y maduros. Tabla 1a-Secuencias de precursores de microARN humano
- Nombre del Precursor
- Secuencia (de 5’ a 3’)* SEC ID Nº
- let-7A-1
- 1
- let-7a-2
- 2
- let-7a-3
- 3
- let-7a-4
-
imagen6 4
- let-7b
-
imagen7 5
- let-7c
- 6
- let-7d
- 7
- let-7d-v1
- 8
- let-7d-v2
- 9
- let-7e
- 10
- let-7f-1
- 11
- let-7f-2-1
- 12
- let-7f-2-2
- 13
- let-7g
- 14
E12165748
07-05-2015 E12165748
- let-7i
- 15
- miR-1b-1-1
-
imagen8 16
- miR-1b-1-2
- 17
- miR-1b-2
- 18
- miR-1b
- 19
- miR-1d
-
imagen9 20
- miR-7-1a
- 21
- miR-7-1b
- 22
- miR-7-2
- 23
- miR-7-3
- 24
- miR-9-1
- 25
- miR-9-2
- 26
- miR-9-3
- 27
- miR-10a
- 28
07-05-2015 E12165748
- miR-10b
- 29
- miR-15a-2
- 30
- miR-15a
- 31
- miR-15b-1
- 32
- miR-15b-2
- 33
- miR-16-1
-
imagen10 34
- miR-16-2
- 35
- miR-16-13
- 36
- miR-17
-
imagen11 37
- miR-18
- 38
- miR-18-13
- 39
- miR-19a
- 40
- miR-19a-13
- 41
- miR-19b-1
-
imagen12 42
- miR-19b-2
- 43
07-05-2015 E12165748
- miR-19b-13
- 44
- miR-19b-X
-
imagen13 45
- miR-20 (miR-20a)
- 46
- miR-21
- 47
- miR-21-17
-
imagen14 48
- miR-22
- 49
- miR-23a
- 50
- miR-23b
- 51
- miR-23-19
- 52
- miR-24-1
-
imagen15 53
- miR-24-2
-
imagen16 54
- miR-24-19
- 55
- miR-24-9
- 56
- miR-25
- 57
- miR-26a
- 58
- miR-26a-1
-
imagen17 59
07-05-2015 E12165748
- miR-26a-2
- 60
- miR-26b
-
imagen18 61
- miR-27a
- 62
- miR-27b-1
- 63
- miR-27b-2
-
imagen19 64
- miR-27-19
- 65
- miR-28
-
imagen20 66
- miR-29a-2
- 67
- miR-29a
- 68
- miR-29b-1
- 69
- miR-29b-2
- 70
- miR-29c
- 71
- miR-30a
- 72
- miR-30b-1
- 73
- miR-30b-2
- 74
- miR-30c
- 75
07-05-2015 E12165748
- miR-30d
- 76
- miR-30e
- 77
- miR-31
-
imagen21 78
- miR-32
- 79
- miR-33b
- 80
- miR-33b-2
- 81
- miR-33
- 82
- miR-34-a
- 83
- miR-34-b
- 84
- miR-34-c
- 85
- miR-91-13
- 86
- miR-92-1
- 87
- miR-92 -2
-
imagen22 88
- miR-93-1 (miR93-2)
- 89
- miR-95-4
- 90
07-05-2015 E12165748
- miR-96-7
- 91
- miR-97-6 (miR30*)
- 92
- miR-98
- 93
- miR-99b
-
imagen23 94
- miR-99a
- 95
- miR-100-1/2
- 96
- miR-100-11
- 97
- miR-101-1/2
- 98
- miR-101
- 99
- miR-101-1
- 100
- miR-101-2
- 101
- miR-101-9
- 102
- miR-102-1
- 103
- miR-102-7.1 (miR-102-7.2)
- 104
- miR-103-2
- 105
07-05-2015 E12165748
- miR-103-1
- 106
- miR-104-17
- 107
- miR-105-1
-
imagen24 108
- miR-105-2
- 109
- miR-106-a
- 110
- miR-106-b
- 111
- miR-107
-
imagen25 112
- miR-108-1pequeño
- 113
- miR-108-2pequeño
-
imagen26 114
- miR-122a-1
- 115
- miR-122a-2
- 116
- miR-123
-
imagen27 117
- miR-124a-1
- 118
- miR-124a-2
- 119
- miR-124a-3
- 120
- miR-124a
- 121
- miR-124b
- 122
07-05-2015 E12165748
- miR-125a-1
- 123
- miR-125a-2
- 124
- miR-125b-1
-
imagen28 125
- miR-125b-2
- 126
- miR-126-1
- 127
- miR-126-2
-
imagen29 128
- miR-127-1
- 129
- miR-127-2
- 130
- miR-128a
- 131
- miR-128b
- 132
- miR-128
- 133
- miR-129-1
- 134
- miR-129-2
- 135
- miR-130a
- 136
- miR-131-1
- 137
07-05-2015 E12165748
- miR-131-3
- 138
- miR-131
- 139
- miR-132-1
- 140
- miR-132-2
-
imagen30 141
- miR-133a-1
-
imagen31 142
- miR-133a-2
- 143
- miR-133
- 144
- miR-133b
- 145
- miR-133bpequeño
- 146
- miR-134-1
- 147
- miR-134-2
- 148
- miR-135a-1
- 149
- miR-135a-2 (miR135-2)
- 150
- miR-135
-
imagen32 151
- miR-135b
- 152
- miR-136-1
-
imagen33 153
07-05-2015 E12165748
- miR-136-2
- 154
- miR-137
- 155
- miR-138-1
-
imagen34 156
- miR-138-2
-
imagen35 157
- miR-138
- 158
- miR-139
- 159
- miR-140
- 160
- miR-140as
-
imagen36 161
- miR-140s
- 162
- miR-141-1
- 163
- miR-141-2
-
imagen37 164
- miR-142
-
imagen38 165
- miR-143-1
- 166
- miR-143-2
- 167
- miR-144-1
- 168
- miR-144-2
- 169
- miR-145-1
- 170
07-05-2015 E12165748
- miR-1 45-2
- 171
- miR-146-1
- 172
- miR-146-2
-
imagen39 173
- miR-147
- 174
- miR-148a (miR148)
- 175
- miR-148b
-
imagen40 176
- miR-148bpequeño
- 177
- miR-149-1
- 178
- miR-149-2
- 179
- miR-150-1
- 180
- miR-150-2
- 181
- miR-151
-
imagen41 182
- miR-151-2
- 183
- miR-152-1
- 184
- miR-152-2
- 185
- miR-153-1-1
- 186
- miR-153-1-2
-
imagen42 187
07-05-2015 E12165748
- miR-153-2-1
- 188
- miR-153-2-2
- 189
- miR-154-1
-
imagen43 190
- miR-154-2
-
imagen44 191
- miR-155
-
imagen45 192
- miR-156 = miR157=solapamiento miR-141
-
imagen46 193
- miR-158pequeño = miR192
-
imagen47 194
- miR-159-1pequeño
-
imagen48 195
- miR-161pequeño
-
imagen49 196
- miR-163-1bpequeño
- 197
- miR-163-3pequeño
- 198
- miR-162
- 199
- miR-175pequeño =miR224
- 200
- miR-177pequeño
- 201
- miR-180pequeño
- 202
07-05-2015 E12165748
- miR-181a
- 203
- miR-181b-1
- 204
- miR-181b-2
-
imagen50 205
- miR-181c
- 206
- miR-182-as
-
imagen51 207
- miR-182
- 208
- miR-183
- 209
- miR-184-1
- 210
- miR-184-2
-
imagen52 211
- miR-185-1
- 212
- miR-185-2
- 213
- miR-186-1
- 214
- miR-186-2
- 215
- miR-187
- 216
- miR-188-1
- 217
07-05-2015 E12165748
- miR-188-2
- 218
- miR-189-1
- 219
- miR-189-2
-
imagen53 220
- miR-190-1
- 221
- miR-190-2
-
imagen54 222
- miR-191-1
- 223
- miR-191-2
- 224
- miR-192-2/3
- 225
- miR-192
- 226
- miR-193-1
- 227
- miR-193-2
- 228
- miR-194-1
-
imagen55 229
- miR-194-2
- 230
- miR-195-1
-
imagen56 231
- miR-195-2
- 232
- miR-196-1
- 233
- miR-196a-1
- 234
07-05-2015 E12165748
- miR-196a-2 (miR196-2)
- 235
- miR-196
-
imagen57 236
- miR-196b
- 237
- miR-197
- 238
- miR-197-2
- 239
- miR-198
- 240
- miR-199a-1
- 241
- miR-199a-2
- 242
- miR-199b
- 243
- miR-199s
- 244
- miR-200a
- 245
- miR-200b
- 246
- miR-200c
-
imagen58 247
- miR-202
- 248
- miR-203
-
imagen59 249
07-05-2015 E12165748
- miR-204
- 250
- miR-205
- 251
- miR-206-1
- 252
- miR-206-2
- 253
- miR-208
- 254
- miR-210
- 255
- miR-211
- 256
- miR-212
-
imagen60 257
- miR-213-2
- 258
- miR-213
- 259
- miR-95-4
- 260
- miR-215
- 261
- miR-216
- 262
07-05-2015 E12165748
- miR-217
- 263
- miR-218-1
-
imagen61 264
- miR-218-2
- 265
- miR-219
- 266
- miR-219-1
- 267
- miR-219-2
- 268
- miR-220
- 269
- miR-221
- 270
- miR-222
- 271
- miR-223
- 272
- miR-95-4
-
imagen62 273
- miR-294-1 (chr16)
- 274
- miR-296
- 275
- miR-299
- 276
07-05-2015 E12165748
- miR-301
- 277
- miR-302a
- 278
- miR-302b
-
imagen63 279
- miR-302c
- 280
- miR-302d
- 281
- miR-320
-
imagen64 282
- miR-321
- 283
- miR-323
-
imagen65 284
- miR-324
-
imagen66 285
- miR-325
- 286
- miR-326
- 287
- miR-328
- 288
- miR-330
- 289
- miR-331
- 290
- miR-335
- 291
- miR-337
- 292
- miR-338
- 293
- miR-339
- 294
07-05-2015
- miR-340
- 295
- miR-342
- 296
- miR-345
- 297
- miR-346
- 298
- miR-367
-
imagen67 299
- miR-368
- 300
- miR-369
- 301
- miR-370
- 302
- miR-371
- 303
- miR-372
- 304
- miR-373
- 305
- miR-374
- 306
- miR-hes1
- 307
- miR-hes2
- 308
- miR-hes3
- 309
- * Una secuencia subrayada dentro de una secuencia de precursor corresponde a un transcrito de miR procesado maduro (véase la Tabla 1b). Algunas secuencias de precursor tienen dos secuencias subrayadas que indican dos miR maduros diferentes que se obtienen a partir del mismo precursor. Todas las secuencias son humanas.
Tabla 1b -Secuencias de microRNA Maduro Humano.
- Nombre de miRNA Maduro
- Secuencia de miRNA Maduro (5’ a 3’) SEC ID Nº microRNA precursor correspondiente(s); véase la Tabla 1a
- let-7a
- ugagguaguagguuguauaguu 310 let-7a-1; let-7a-2; let-7a-3; let-7a-4
- let-7b
- ugagguaguagguugugugguu 311
- let-7b
- let-7c
- ugagguaguagguuguaugguu 312
- let-7c
- let-7d
- agagguaguagguugcauagu 313 let-7d; let-7d-v1
- let-7e
- ugagguaggagguuguauagu 314
- let-7e
- let-7f
- ugagguaguagauuguauaguu 315 let-7f-1; let-7f-2-1; let-7f-2-2
E12165748
07-05-2015 E12165748
- let-7g
- ugagguaguaguuuguacagu 316
- let-7g
- let-7i
- ugagguaguaguuugugcu 317
- let-7i
- miR-1
- uggaauguaaagaaguaugua 318 miR-1b; miR-1b-1; miR-1b-2
- miR-7
- uggaagacuagugauuuuguu 319 miR-7-1; miR-7-1a; miR-7-2; miR-7-3
- miR-9
- ucuuugguuaucuagcuguauga 320 miR-9-1; miR-9-2; miR-9-3
- miR-9*
- uaaagcuagauaaccgaaagu 321 miR-9-1; miR-9-2; miR-9-3
- miR-10a
- uacccuguagauccgaauuugug 322
- miR-10a
- miR-10b
- uacccuguagaaccgaauuugu 323
- miR-10b
- miR-15a
- uagcagcacauaaugguuugug 324 miR-15a; miR-15a-2
- miR-15b
- uagcagcacaucaugguuuaca 325
- miR-15b
- miR-16
- uagcagcacguaaauauuggcg 326 miR-16-1; miR-16-2; miR-16-13
- miR-17-5p
- caaagugcuuacagugcagguagu 327 miR-17
- miR-17-3p
- acugcagugaaggcacuugu 328 miR-17
- miR-18
- uaaggugcaucuagugcagaua 329 miR-18; miR-18-13
- miR-19a
- ugugcaaaucuaugcaaaacuga 330 miR-19a; miR-19a-13
- miR-19b
- ugugcaaauccaugcaaaacuga 331 miR-19b-1; miR-19b-2
- miR-20
- uaaagugcuuauagugcaggua 332 miR-20 (miR-20a)
- miR-21
- uagcuuaucagacugauguuga 333 miR-21; miR-21-17
- miR-22
- aagcugccaguugaagaacugu 334
- miR-22
- miR-23a
- aucacauugccagggauuucc 335
- miR-23a
- miR-23b
- aucacauugccagggauuaccac 336
- miR-23b
- miR-95-4
- uggcucaguucagcaggaacag 337 miR-24-1; miR-24-2; miR-24-19; miR24-9
- miR-25
- cauugcacuugucucggucuga 338
- miR-25
- miR-26a
- uucaaguaauccaggauaggcu 339 miR-26a; miR-26a-1; miR-26a-2
- miR-26b
- uucaaguaauucaggauaggu 340
- miR-26b
- miR-27a
- uucacaguggcuaaguuccgcc 341
- miR-27a
- miR-27b
- uucacaguggcuaaguucug 342 miR-27b-1; miR-27b-2
- miR-28
- aaggagcucacagucuauugag 343
- miR-28
- miR-29a
- cuagcaccaucugaaaucgguu 344 miR-29a-2; miR-29a
- miR-29b
- uagcaccauuugaaaucagu 345 miR-29b-1; miR-29b-2
- miR-29c
- uagcaccauuugaaaucgguua 346
- miR-29c
- miR-30a-5p
- uguaaacauccucgacuggaagc 347 miR-30a
- miR-30a-3p
- cuuucagucggauguuugcagc 348 miR-30a
- miR-30b
- uguaaacauccuacacucagc 349 miR-30b-1; miR-30b-2
- miR-30c
- uguaaacauccuacacucucagc 350
- miR-30c
- miR-30d
- uguaaacauccccgacuggaag 351
- miR-30d
- miR-30e
- uguaaacauccuugacugga 352
- miR-30e
- miR-31
- ggcaagaugcuggcauagcug 353
- miR-31
- miR-32
- uauugcacauuacuaaguugc 354
- miR-32
- miR-33
- gugcauuguaguugcauug 355 miR-33; miR-33b
- miR-34a
- uggcagugucuuagcugguugu 356
- miR-34a
- miR-34b
- aggcagugucauuagcugauug 357
- miR-34b
- miR-34c
- aggcaguguaguuagcugauug 358
- miR-34c
- miR-92
- uauugcacuugucccggccugu 359 miR-92-2; miR-92-1
- miR-93
- aaagugcuguucgugcagguag 360 miR-93-1; miR-93-2
- miR-95
- uucaacggguauuuauugagca 361
- miR-95
- miR-96
- uuuggcacuagcacauuuuugc 362
- miR-96
- miR-98
- ugagguaguaaguuguauuguu 363
- miR-98
- miR-99a
- aacccguagauccgaucuugug 364
- miR-99a
- miR-99b
- cacccguagaaccgaccuugcg 365
- miR-99b
- miR-100
- uacaguacugugauaacugaag 366
- miR-100
- miR-101
- uacaguacugugauaacugaag 367 miR-101-1; miR-101-2
- miR-103
- agcagcauuguacagggcuauga 368 miR-103-1
- miR-105
- ucaaaugcucagacuccugu 369
- miR-105
- miR-106-a
- aaaagugcuuacagugcagguagc 370
- miR-106-a
- miR-106-b
- uaaagugcugacagugcagau 371
- miR-106-b
- miR-107
- agcagcauuguacagggcuauca 372
- miR-107
- miR-122a
- uggagugugacaaugguguuugu 373 miR-122a-1; miR-122a-2
- miR-124a
- uuaaggcacgcggugaaugcca 374 miR-124a-1; miR-124a-2; miR-124a-3
- miR-125a
- ucccugagacccuuuaaccugug 375 miR-125a-1; miR-125a-2
07-05-2015 E12165748
- miR-125b
- ucccugagacccuaacuuguga 376 miR-125b-1; miR-125b-2
- miR-126*
- cauuauuacuuuugguacgcg 377 miR-126-1; miR-126-2
- miR-126
- ucguaccgugaguaauaaugc 378 miR-126-1; miR-126-2
- miR-127
- ucggauccgucugagcuuggcu 379 miR-127-1; miR-127-2
- miR-128a
- ucacagugaaccggucucuuuu 380 miR-128; miR-128a
- miR-128b
- ucacagugaaccggucucuuuc 381
- miR-128b
- miR-129
- cuuuuugcggucugggcuugc 382 miR-129-1; miR-129-2
- miR-130a
- cagugcaauguuaaaagggc 383
- miR-130a
- miR-130b
- cagugcaaugaugaaagggcau 384
- miR-130b
- miR-132
- uaacagucuacagccauggucg 385 miR-132-1
- miR-133a
- uugguccccuucaaccagcugu 386 miR-133a-1; miR-133a-2
- miR-133b
- uugguccccuucaaccagcua 387
- miR-133b
- miR-95-4
- ugugacugguugaccagaggg 388 miR-134-1; miR-134-2
- miR-135a
- uauggcuuuuuauuccuauguga 389 miR-135a; miR-135a-2 (miR-135-2)
- miR-135b
- uauggcuuuucauuccuaugug 390
- miR-135b
- miR-136
- acuccauuuguuuugaugaugga 391 miR-136-1; miR-136-2
- miR-137
- uauugcuuaagaauacgcguag 392
- miR-137
- miR-138
- agcugguguugugaauc 393 miR-138-1; miR-138-2
- miR-139
- ucuacagugcacgugucu 394
- miR-139
- miR-140
- agugguuuuacccuaugguag 395 miR-140; miR-140as; miR-140s
- miR-141
- aacacugucugguaaagaugg 396 miR-141-1; miR-141-2
- miR-142-3p
- uguaguguuuccuacuuuaugga 397 miR-142
- miR-142-5p
- cauaaaguagaaagcacuac 398 miR-142
- miR-143
- ugagaugaagcacuguagcuca 399 miR-143-1
- miR-144
- uacaguauagaugauguacuag 400 miR-144-1; miR-144-2
- miR-145
- guccaguuuucccaggaaucccuu 401 miR-145-1; miR-145-2
- miR-146
- ugagaacugaauuccauggguu 402 miR-146-1; miR-146-2
- miR-147
- guguguggaaaugcuucugc 403
- miR-147
- miR-148a
- ucagugcacuacagaacuuugu 404 miR-148a (miR-148)
- miR-148b
- ucagugcaucacagaacuuugu 405
- miR-148b
- miR-149
- ucuggcuccgugucuucacucc 406
- miR-149
- miR-150
- ucucccaacccuuguaccagug 407 miR-150-1; miR-150-2
- miR-151
- acuagacugaagcuccuugagg 408
- miR-151
- miR-152
- ucagugcaugacagaacuugg 409 miR-152-1; miR-152-2
- miR-153
- uugcauagucacaaaaguga 410 miR-153-1-1; miR-153-1-2; miR-1532-1; m iR-153-2-2
- miR-154
- uagguuauccguguugccuucg 411 miR-154-1; miR-154-2
- miR-154*
- aaucauacacgguugaccuauu 412 miR-154-1; miR-154-2
- miR-155
- uuaaugcuaaucgugauagggg 413
- miR-155
- miR-181a
- aacauucaacgcugucggugagu 414
- miR-181a
- miR-181b
- aacauucauugcugucgguggguu 415 miR-181b-1; miR-181b-2
- miR-181c
- aacauucaaccugucggugagu 416
- miR-181c
- miR-182
- uuuggcaaugguagaacucaca 417 miR-182; miR-182as
- miR-182*
- ugguucuagacuugccaacua 418 miR-182; miR-182as
- miR-183
- uauggcacugguagaauucacug 419
- miR-183
- miR-95-4
- uggacggagaacugauaagggu 420 miR-184-1; miR-184-2
- miR-185
- uggagagaaaggcaguuc 421 miR-185-1; miR-185-2
- miR-186
- caaagaauucuccuuuugggcuu 422 miR-186-1; miR-186-2
- miR-187
- ucgugucuuguguugcagccg 423
- miR-187
- miR-188
- caucccuugcaugguggagggu 424
- miR-188
- miR-189
- gugccuacugagcugauaucagu 425 miR-189-1; miR-189-2
- miR-190
- ugauauguuugauauauuaggu 426 miR-190-1; miR-190-2
- miR-191
- caacggaaucccaaaagcagcu 427 miR-191-1; miR-191-2
- miR-192
- cugaccuaugaauugacagcc 428
- miR-192
- miR-193
- aacuggccuacaaagucccag 429 miR-193-1; miR-193-2
- miR-95-4
- uguaacagcaacuccaugugga 430 miR-194-1; miR-194-2
- miR-195
- uagcagcacagaaauauuggc 431 miR-195-1; miR-195-2
- miR-196a
- uagguaguuucauguuguugg 432 miR-196a; miR-196a-2 (miR19
- miR-196b
- uagguaguuuccuguuguugg 433
- miR-196b
- miR-197
- uucaccaccuucuccacccagc 434
- miR-197
- miR-198
- gguccagaggggagauagg 435
- miR-198
07-05-2015
- miR-199a
- cccaguguucagacuaccuguuc 436 miR-199a-1; miR-199a-2
- miR-199a*
- uacaguagucugcacauugguu 437 miR-199a-1; miR-199a-2; miR-199s; miR-199b
- miR-199b
- cccaguguuuagacuaucuguuc 438
- miR-199b
- miR-200a
- uaacacugucugguaacgaugu 439
- miR-200a
- miR-200b
- cucuaauacugccugguaaugaug 440
- miR-200b
- miR-200c
- aauacugccggguaaugaugga 441
- miR-200c
- miR-202
- agagguauagggcaugggaaga 442
- miR-202
- miR-203
- gugaaauguuuaggaccacuag 443
- miR-203
- miR-204
- uucccuuugucauccuaugccu 444
- miR-204
- miR-205
- uccuucauuccaccggagucug 445
- miR-205
- miR-206
- uggaauguaaggaagugugugg 446 miR-206-1; miR-206-2
- miR-208
- auaagacgagcaaaaagcuugu 447
- miR-208
- miR-210
- cugugcgugugacagcggcug 448
- miR-210
- miR-211
- uucccuuugucauccuucgccu 449
- miR-211
- miR-212
- uaacagucuccagucacggcc 450
- miR-212
- miR-213
- accaucgaccguugauuguacc 451
- miR-213
- miR-214
- acagcaggcacagacaggcag 452 miR-95-4
- miR-215
- augaccuaugaauugacagac 453
- miR-215
- miR-216
- uaaucucagcuggcaacugug 454
- miR-216
- miR-217
- uacugcaucaggaacugauuggau 455
- miR-217
- miR-218
- uugugcuugaucuaaccaugu 456 miR-218-1; miR-218-2
- miR-219
- ugauuguccaaacgcaauucu 457 miR-219; miR-219-1; miR-219-2
- miR-220
- ccacaccguaucugacacuuu 458
- miR-220
- miR-221
- agcuacauugucugcuggguuuc 459
- miR-221
- miR-222
- agcuacaucuggcuacugggucuc 460
- miR-222
- miR-223
- ugucaguuugucaaauacccc 461
- miR-223
- miR-224
- caagucacuagugguuccguuua 462
- miR-224
- miR-296
- agggcccccccucaauccugu 463
- miR-296
- miR-299
- ugguuuaccgucccacauacau 464
- miR-299
- miR-301
- cagugcaauaguauugucaaagc 465
- miR-301
- miR-302a
- uaagugcuuccauguuuugguga 466
- miR-302a
- miR-302b*
- acuuuaacauggaagugcuuucu 467 miR-302b
- miR-302b
- uaagugcuuccauguuuuaguag 468
- miR-302b
- miR-302c*
- uuuaacauggggguaccugcug 469 miR-302c
- miR-302c
- uaagugcuuccauguuucagugg 470
- miR-302c
- miR-302d
- uaagugcuuccauguuugagugu 471
- miR-302d
- miR-320
- aaaagcuggguugagagggcgaa 472
- miR-320
- miR-321
- uaagccagggauuguggguuc 473
- miR-321
- miR-323
- gcacauuacacggucgaccucu 474
- miR-323
- miR-324-5p
- cgcauccccuagggcauuggugu 475 miR-324
- miR-324-3p
- ccacugccccaggugcugcugg 476 miR-324
- miR-325
- ccuaguagguguccaguaagu 477
- miR-325
- miR-326
- ccucugggcccuuccuccag 478
- miR-326
- miR-328
- cuggcccucucugcccuuccgu 479
- miR-328
- miR-330
- gcaaagcacacggccugcagaga 480
- miR-330
- miR-331
- gccccugggccuauccuagaa 481
- miR-331
- miR-335
- ucaagagcaauaacgaaaaaugu 482
- miR-335
- miR-337
- uccagcuccuauaugaugccuuu 483
- miR-337
- miR-338
- uccagcaucagugauuuuguuga 484
- miR-338
- miR-339
- ucccuguccuccaggagcuca 485
- miR-339
- miR-340
- uccgucucaguuacuuuauagcc 486
- miR-340
- miR-342
- ucucacacagaaaucgcacccguc 487
- miR-342
- miR-345
- ugcugacuccuaguccagggc 488
- miR-345
- miR-346
- ugucugcccgcaugccugccucu 489
- miR-346
- miR-367
- aauugcacuuuagcaaugguga 490
- miR-367
- miR-368
- acauagaggaaauuccacguuu 491
- miR-368
- miR-369
- aauaauacaugguugaucuuu 492
- miR-369
- miR-370
- gccugcugggguggaaccugg 493
- miR-370
- miR-371
- gugccgccaucuuuugagugu 494
- miR-371
- miR-372
- aaagugcugcgacauuugagcgu 495
- miR-372
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75640006P | 2006-01-05 | 2006-01-05 | |
US756400P | 2006-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2536438T3 true ES2536438T3 (es) | 2015-05-25 |
Family
ID=38256884
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12165748.0T Active ES2536438T3 (es) | 2006-01-05 | 2007-01-03 | Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
ES07717734T Active ES2429404T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón |
ES12165740.7T Active ES2553442T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
ES12165734.0T Active ES2554531T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07717734T Active ES2429404T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón |
ES12165740.7T Active ES2553442T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
ES12165734.0T Active ES2554531T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
Country Status (8)
Country | Link |
---|---|
US (3) | US7943318B2 (es) |
EP (4) | EP1978986B1 (es) |
JP (1) | JP5451077B2 (es) |
CN (3) | CN101400361B (es) |
AU (1) | AU2007205234B2 (es) |
CA (1) | CA2633674A1 (es) |
ES (4) | ES2536438T3 (es) |
WO (1) | WO2007081720A2 (es) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1713938A2 (en) * | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
CA2850323A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
EP1937845B1 (en) | 2005-08-01 | 2015-06-10 | The Ohio State University Research Foundation | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer |
EP1937280B1 (en) | 2005-09-12 | 2014-08-27 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers |
EP2487253B1 (en) | 2006-01-05 | 2015-06-24 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
US7943318B2 (en) | 2006-01-05 | 2011-05-17 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
EP2591794A1 (en) | 2006-01-05 | 2013-05-15 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
EP1996731A2 (en) | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
US8207325B2 (en) * | 2006-04-03 | 2012-06-26 | Univ. of Copenhagen | MicroRNA biomarkers for human breast and lung cancer |
EP2455494B1 (en) | 2006-07-13 | 2013-12-18 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
AU2007346101B2 (en) | 2006-09-19 | 2013-08-15 | The Ohio State University Research Foundation | TCL1 expression in chronic lymphocytic leukemia (CLL) regulated by miR-29 and miR-181 |
EP2487240B1 (en) * | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
CN103555825B (zh) | 2007-01-31 | 2015-09-30 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
AU2008248319B2 (en) * | 2007-04-30 | 2013-09-05 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
JP5690588B2 (ja) | 2007-06-08 | 2015-03-25 | アメリカ合衆国 | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 |
CN101918424A (zh) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白 |
EP2808398A1 (en) * | 2007-07-31 | 2014-12-03 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting DNMT3A and DNMT3B |
AU2008283795B2 (en) | 2007-07-31 | 2013-11-21 | Board Of Regents, The University Of Texas System | A micro-RNA family that modulates fibrosis and uses thereof |
ES2627059T3 (es) | 2007-08-03 | 2017-07-26 | The Ohio State University Research Foundation | Regiones ultraconservadas que codifican ARNnc |
EP2188395A4 (en) * | 2007-08-17 | 2010-10-13 | Catalyst Assets Llc | USE OF MICRO-RNA ASSOCIATED WITH CANCER OF THE HUMAN BLADDER FOR DIAGNOSIS AND PROGNOSIS |
CA2696887C (en) | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
WO2009024790A1 (en) * | 2007-08-23 | 2009-02-26 | Isis Innovation Limited | Method and kit for the prognosis of cancer by determining the level of mirna-210 |
US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
JPWO2009044899A1 (ja) * | 2007-10-03 | 2011-02-17 | 協和発酵キリン株式会社 | 細胞の増殖を制御する核酸 |
JP5723156B2 (ja) * | 2007-10-11 | 2015-05-27 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | 食道腺癌の診断及び治療のための方法及び組成物 |
US20090186015A1 (en) * | 2007-10-18 | 2009-07-23 | Latham Gary J | Micrornas differentially expressed in lung diseases and uses thereof |
JP2011504093A (ja) | 2007-10-26 | 2011-02-03 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 脆弱性ヒスチジン三連構造(fhit)相互作用を同定するための方法およびその使用 |
EP2215263A1 (en) | 2007-10-30 | 2010-08-11 | Veridex LLC | Process for predicting the prognosis of squamous cell lung cancer |
US20100323357A1 (en) * | 2007-11-30 | 2010-12-23 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
JP5116026B2 (ja) * | 2008-01-23 | 2013-01-09 | 富士フイルム株式会社 | 癌の検出方法および癌抑制剤 |
EP2247750A4 (en) * | 2008-02-01 | 2011-10-26 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS RELATING TO CANCER STEM CELLS |
JP5662166B2 (ja) * | 2008-02-28 | 2015-01-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | 胃癌の診断、予後診断及び治療のためのマイクロrnaに基づいた方法及び組成物 |
EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
CA2725978A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
EP2294218A2 (en) * | 2008-06-02 | 2011-03-16 | New York University | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
US8927207B2 (en) * | 2008-06-05 | 2015-01-06 | Research Foundation Of State University Of New York | miRNAs as therapeutic targets in cancer |
US9125923B2 (en) | 2008-06-11 | 2015-09-08 | The Ohio State University | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy |
US20110077168A1 (en) * | 2008-06-17 | 2011-03-31 | Nitzan Rosenfeld | Methods for distinguishing between specific types of lung cancers |
EP2145964A1 (en) * | 2008-07-17 | 2010-01-20 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
JP2012507300A (ja) * | 2008-10-30 | 2012-03-29 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Rnaパターンを評価する方法 |
US7897356B2 (en) * | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
CN101475984A (zh) * | 2008-12-15 | 2009-07-08 | 江苏命码生物科技有限公司 | 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒 |
US20100240049A1 (en) | 2009-01-16 | 2010-09-23 | Cepheid | Methods of Detecting Cervical Cancer |
EP2379720B1 (en) | 2009-01-20 | 2016-08-17 | Alona Zilberberg | Mir-21 promoter driven targeted cancer therapy |
WO2010093907A2 (en) * | 2009-02-13 | 2010-08-19 | The Board Of Regents Of The University Of Texas System | An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1 |
WO2010094155A1 (en) * | 2009-02-23 | 2010-08-26 | Capitalbio Corporation | Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival |
EP2401406A4 (en) * | 2009-02-25 | 2012-09-19 | Cepheid | METHODS OF DETECTING LUNG CANCER |
EP2401405A4 (en) * | 2009-02-26 | 2013-10-16 | Univ Ohio State Res Found | MICROARN IN NON-SMOKERS AND METHODS AND RELATED MATERIALS |
IT1398768B1 (it) * | 2009-03-24 | 2013-03-18 | Zollo | Uso di microrna-199b-5p in campo medico e diagnostico. |
CA2754412A1 (en) | 2009-03-31 | 2010-10-14 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjogren's syndrome |
US20110105585A1 (en) * | 2009-04-23 | 2011-05-05 | Northwestern University | METHODS FOR DIAGNOSING AND TREATING SQUAMOUS CELL CARCINOMA UTILIZING miRNA-205 AND INHIBITORS THEREOF |
EP2336353A1 (en) * | 2009-12-17 | 2011-06-22 | febit holding GmbH | miRNA fingerprints in the diagnosis of diseases |
JP5546064B2 (ja) * | 2009-07-09 | 2014-07-09 | 中国医学科学院▲腫▼瘤研究所 | 肺がん予後および薬物調製における2つのマイクロRNAsの使用 |
PL212748B1 (pl) * | 2009-07-30 | 2012-11-30 | Gdanski Univ Medyczny | Sposób okreslania ryzyka odleglego nawrotu niedrobnokomórkowego raka pluca u chorych w stopniu I-III A zaawansowania leczonych chirurgicznie |
WO2011014697A1 (en) * | 2009-07-31 | 2011-02-03 | The Translational Genomics Research Institute | Methods of assessing a risk of cancer progression |
EP2775300A3 (en) * | 2009-08-28 | 2015-04-01 | Asuragen, INC. | miRNA Biomarkers of Lung Disease |
CN102018963B (zh) * | 2009-09-11 | 2013-03-13 | 中国科学院上海生命科学研究院 | 调节RANTES表达的miR-125a、其组合物及其用途 |
WO2011040613A1 (ja) * | 2009-10-01 | 2011-04-07 | 独立行政法人国立がん研究センター | 腫瘍治療剤 |
US20120219632A1 (en) * | 2009-11-02 | 2012-08-30 | Agency For Science, Technology And Research | Methods for monitoring cellular states and for immortalizing mesenchymal stem cell |
US8916533B2 (en) | 2009-11-23 | 2014-12-23 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
CN102080083B (zh) * | 2009-12-01 | 2013-02-27 | 中国科学院上海药物研究所 | 人miR-149反义核酸及其应用 |
WO2011084815A1 (en) * | 2009-12-21 | 2011-07-14 | Board Of Trustees Of Southern Illinois University | Inhibition of ubc9-mediated cancer cell invasion and metastasis |
CN102782155B (zh) * | 2009-12-24 | 2016-05-04 | 复旦大学 | 用于肺癌的血浆中微rna表达谱分析的组合物和方法 |
CN102770561B (zh) * | 2009-12-24 | 2015-05-06 | 复旦大学 | 用于诊断不同亚型肺癌的基于组织的微-rna方法 |
WO2011076145A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Tissue-based micro-rna methods for diagnosis of different subtypes of lung cancer |
EP2542696B1 (en) | 2010-03-01 | 2016-09-28 | Caris Life Sciences Switzerland Holdings GmbH | Biomarkers for theranostics |
WO2011115884A1 (en) * | 2010-03-18 | 2011-09-22 | Centocor Ortho Biotech Inc. | Diagnostic for lung cancer using mirna |
CN103025384B (zh) * | 2010-03-26 | 2016-04-20 | 俄亥俄州立大学 | 涉及miR-155对于错配修复和基因组稳定性的调节的材料和方法 |
JPWO2011125245A1 (ja) * | 2010-04-05 | 2013-07-08 | 公益財団法人がん研究会 | miRNAを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法 |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
WO2011150855A1 (en) * | 2010-06-04 | 2011-12-08 | Fudan University | Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma |
WO2011156777A1 (en) | 2010-06-10 | 2011-12-15 | Fred Hutchinson Cancer Research Center | Use of blood mir-210 for cancer prognosis |
NZ719520A (en) | 2010-07-06 | 2017-07-28 | Int Tech Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
US9006201B2 (en) | 2010-07-08 | 2015-04-14 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for diabetes |
CN103648505B (zh) | 2010-11-12 | 2016-09-28 | 俄亥俄州立大学研究基金会 | 与微rna-21、错配修复和结肠直肠癌相关的材料和方法 |
BR112013011942A2 (pt) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. |
EP2505663A1 (en) | 2011-03-30 | 2012-10-03 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | A method to identify asymptomatic high-risk individuals with early stage lung cancer by means of detecting miRNAs in biologic fluids |
CN102140466B (zh) * | 2010-12-30 | 2013-03-27 | 苏州吉玛基因股份有限公司 | 人miR-1825反义核酸及其应用 |
CN102140467B (zh) * | 2010-12-30 | 2013-05-15 | 苏州吉玛基因股份有限公司 | 人miR-365反义核酸及其应用 |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
WO2012097047A1 (en) * | 2011-01-11 | 2012-07-19 | The Ohio State University Research Foundation | Methods to identify chronic lymphocytic leukemia disease progression |
CN102586412B (zh) * | 2011-01-18 | 2015-05-20 | 上海市第一人民医院 | 一种MicroRNA特异表达谱及其应用 |
US20120244530A1 (en) | 2011-01-26 | 2012-09-27 | Cepheid | Methods of detecting lung cancer |
EP2670849A1 (en) | 2011-02-03 | 2013-12-11 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
IT1406866B1 (it) * | 2011-02-07 | 2014-03-14 | Fond Irccs Istituto Naz Dei Tumori | Procedimento ed apparecchiatura per identificare individui a rischio di tumore polmonare e/o per diagnosticare un tumore polmonare, nonché composizione e metodo per ridurre o eliminare il rischio di tumore polmonare |
IT1403685B1 (it) * | 2011-02-07 | 2013-10-31 | Fond Irccs Istituto Naz Dei Tumori | Procedimento ed apparecchiatura per identificare individui a rischio di tumore polmonare e/o per diagnosticare un tumore polmonare, nonche' composizione e metodo per ridurre o eliminare il rischio di tumore polmonare. |
WO2012107841A2 (en) | 2011-02-07 | 2012-08-16 | Biomirna Holdings Ltd. | Micro-rna biomarkers and methods of using same |
AU2012225506B2 (en) | 2011-03-07 | 2016-11-17 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
JP2014509522A (ja) | 2011-03-28 | 2014-04-21 | ロゼッタ ゲノミクス リミテッド | 肺癌を分類するための方法 |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
CA2852066A1 (en) | 2011-10-14 | 2013-04-18 | The Ohio State University | Methods and materials related to ovarian cancer |
JP2015501843A (ja) | 2011-12-13 | 2015-01-19 | オハイオ・ステイト・イノベーション・ファウンデーション | miR−21およびmiR−29a、エキソソーム阻害、およびがん転移に関する方法および組成物 |
WO2013090620A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
CN102533983A (zh) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | 癌症病理演变前期microrna-330水平原位杂交检测试剂盒及检测方法和应用 |
CN102533984A (zh) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | 癌症病理演变前期microrna17-3p水平原位杂交检测试剂盒及检测方法和应用 |
ITRM20110685A1 (it) | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
CN102559884A (zh) * | 2011-12-27 | 2012-07-11 | 芮屈生物技术(上海)有限公司 | 各种癌症病理演变前期let-7mirna水平原位杂交检测试剂盒及检测方法和应用 |
CN104685065B (zh) | 2012-01-20 | 2017-02-22 | 俄亥俄州立大学 | 浸润性和预后的乳腺癌生物标志物标签 |
CN102776194A (zh) * | 2012-07-20 | 2012-11-14 | 苏州大学 | 微小rna用于调控pten基因表达 |
US10196662B2 (en) * | 2012-08-10 | 2019-02-05 | Mello Biotechnology, Inc. | Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors |
DK3435084T3 (da) | 2012-08-16 | 2023-05-30 | Mayo Found Medical Education & Res | Prostatakræftprognose under anvendelse af biomarkører |
KR101501826B1 (ko) * | 2013-04-05 | 2015-03-13 | 연세대학교 산학협력단 | 위암에 대한 예후 예측 모형의 제조방법 |
CN103285406B (zh) * | 2013-05-27 | 2015-05-13 | 哈尔滨医科大学 | microRNA-203及其拟似物在制备防治肥胖、血脂异常及其并发症药物中的应用 |
CN103751801A (zh) * | 2013-09-10 | 2014-04-30 | 上海大学 | 非小细胞肺癌中miR-143基因的应用 |
PL405648A1 (pl) | 2013-10-15 | 2015-04-27 | Warszawski Uniwersytet Medyczny | Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny |
PL406033A1 (pl) | 2013-11-14 | 2015-05-25 | Warszawski Uniwersytet Medyczny | Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny |
CN103948926A (zh) * | 2014-03-24 | 2014-07-30 | 江苏大学 | miR-9抑制剂在制备用于抑制肿瘤生长药物中的用途 |
CN104031987B (zh) * | 2014-05-12 | 2016-08-31 | 贵州省人民医院 | miRNA在心肌纤维化疾病治疗中的应用 |
CN104152452B (zh) * | 2014-08-19 | 2016-08-24 | 中国人民解放军总医院第一附属医院 | 一种与肝癌相关的血液miRNA标志物及其应用 |
US20160070852A1 (en) * | 2014-09-04 | 2016-03-10 | National Taiwan University | Prognosis prediction for acute myeloid leukemia by a 3-microrna scoring method |
CN104911248A (zh) * | 2014-12-18 | 2015-09-16 | 南京大学 | 一种用于ii、iii期结直肠癌诊断及预后的微小核糖核酸组合及其应用 |
CN104726448B (zh) * | 2014-12-29 | 2018-03-30 | 常州杰傲病理诊断技术有限公司 | 一种用于肺癌组织分型的miRNA标志物及应用 |
JP2018524972A (ja) * | 2015-05-19 | 2018-09-06 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 肺癌の診断または検出のための方法及び組成物 |
RU2718534C2 (ru) | 2015-06-05 | 2020-04-08 | Мираджен Терапьютикс, Инк. | Ингибиторы mir-155 для лечения кожной t-клеточной лимфомы (ctcl) |
CN105457041B (zh) * | 2015-12-09 | 2020-09-08 | 上海大学 | miR-26a在非小细胞肺癌中的应用 |
CN105561339B (zh) * | 2015-12-21 | 2019-02-22 | 江苏省人民医院 | 一种miRNA的组合制备抗非小细胞肺癌药物中的应用 |
CN105726559B (zh) * | 2016-03-21 | 2018-12-18 | 南通大学 | miRNA-17-3p和miRNA-19b-1组合物及其应用 |
ES2646826B1 (es) * | 2016-05-13 | 2018-10-01 | Servicio Andaluz De Salud | MicroARNs como biomarcadores para el diagnóstico del cáncer de pulmón |
US20200318110A1 (en) * | 2016-05-27 | 2020-10-08 | Lin Shi Lung | A composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancer |
CN106055921A (zh) * | 2016-05-27 | 2016-10-26 | 华中农业大学 | 基于基因表达和药物靶标的药物活性预测与筛选方法 |
US11053496B2 (en) | 2016-06-14 | 2021-07-06 | Agency For Science, Technology And Research | Consequences of a defective switch in cutaneous squamous cell carcinoma |
CN105950753B (zh) * | 2016-06-16 | 2019-10-01 | 朱伟 | 一种与肺腺癌辅助诊断相关的血浆miRNA标志物及其应用 |
KR101888744B1 (ko) | 2016-08-02 | 2018-10-04 | 연세대학교 산학협력단 | Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법 |
WO2018039490A1 (en) | 2016-08-24 | 2018-03-01 | Genomedx Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
US10738363B2 (en) | 2016-08-31 | 2020-08-11 | National Central University | Analyzer and analytical method for predicting prognosis of cancer radiotherapy |
BR112019008810A2 (pt) | 2016-11-01 | 2019-07-16 | Univ New York State Res Found | micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer |
US20220389420A1 (en) * | 2016-11-25 | 2022-12-08 | Centre National De La Recherche Scientifique | Agents for the treatment of patients with nsclc and methods to predict response |
CN107058480B (zh) * | 2016-12-14 | 2018-07-13 | 河北医科大学第四医院(河北省肿瘤医院) | 用于诊断肺腺癌的长链非编码rna标志物 |
AU2018210695A1 (en) | 2017-01-20 | 2019-08-08 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
US10314855B2 (en) * | 2017-01-23 | 2019-06-11 | Trustees Of Boston University | Methods relating to lung cancer |
CN106755521B (zh) * | 2017-02-20 | 2019-03-08 | 南京盖斯夫医药科技有限公司 | 血浆microRNAs用于制备筛查诊断女性群体中肺腺癌患者的诊断试剂的用途 |
EP3593140A4 (en) | 2017-03-09 | 2021-01-06 | Decipher Biosciences, Inc. | SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY |
CA3062716A1 (en) | 2017-05-12 | 2018-11-15 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
CN113604564A (zh) * | 2017-08-14 | 2021-11-05 | 江苏为真生物医药技术股份有限公司 | 一种检测外泌体相关microRNA分子的方法 |
CN107475388B (zh) * | 2017-08-22 | 2020-05-19 | 深圳市恩普电子技术有限公司 | 鼻咽癌相关的miRNA作为生物标志物的应用及鼻咽癌检测试剂盒 |
CN108096266A (zh) * | 2017-11-30 | 2018-06-01 | 佛山英特医药科技有限公司 | miRNA-370在抗肿瘤作用、实施方法及用途 |
CN108841962B (zh) * | 2018-08-01 | 2021-11-19 | 博奥生物集团有限公司 | 一种非小细胞肺癌检测试剂盒及其应用 |
CN109207599A (zh) * | 2018-11-12 | 2019-01-15 | 觅瑞(杭州)生物科技有限公司 | 一种用于非小细胞肺癌诊断的外周血miRNA标志物 |
JP2020092688A (ja) * | 2018-12-12 | 2020-06-18 | 国立大学法人東海国立大学機構 | マイクロrnaを含む体液抽出物 |
CN109385478B (zh) * | 2018-12-20 | 2021-08-03 | 首都医科大学附属北京朝阳医院 | 检测19-gcs的基因标记在制备用于诊断早期肺腺癌预后的产品中的应用 |
CN111218513B (zh) * | 2020-04-24 | 2020-08-14 | 上海思路迪医学检验所有限公司 | 一种用于肺癌早期诊断的外周血胞外囊泡microRNA生物标志物及其用途 |
WO2023074135A1 (ja) * | 2021-11-01 | 2023-05-04 | 国立研究開発法人国立がん研究センター | 肺がんの予後の判定を補助する方法及び試薬キット |
CN116585342A (zh) * | 2023-05-23 | 2023-08-15 | 源生生物科技(青岛)有限责任公司 | 包含miRNA的活性成分及其应用 |
CN117286252B (zh) * | 2023-11-16 | 2024-04-09 | 上海交通大学医学院 | 一种诊断和预后评估肺癌的生物标志物组合及其应用 |
Family Cites Families (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4608337A (en) | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4701409A (en) | 1984-11-15 | 1987-10-20 | The Wistar Institute | Detection of B-cell neoplasms |
US4693975A (en) | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4712124A (en) * | 1986-12-22 | 1987-12-08 | North American Philips Corporation | Complementary lateral insulated gate rectifiers with matched "on" resistances |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
EP0341904B1 (en) | 1988-05-09 | 1995-03-29 | Temple University of the Commonwealth System of Higher Education | Method for predicting the effectiveness of antineoplastic therapy in individual patients |
US5198338A (en) | 1989-05-31 | 1993-03-30 | Temple University | Molecular probing for human t-cell leukemia and lymphoma |
US5149628A (en) | 1989-11-15 | 1992-09-22 | Temple University | Methods for detecting bcl-3 gene in human leukemias |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5633135A (en) | 1991-12-11 | 1997-05-27 | Thomas Jefferson University | Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities |
US6040140A (en) | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
WO1993012136A1 (en) | 1991-12-11 | 1993-06-24 | Thomas Jefferson University | Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
JPH08502889A (ja) | 1992-10-29 | 1996-04-02 | トーマス・ジェファーソン・ユニバーシティ | 前立腺癌の微小転移を検出する方法 |
US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5985598A (en) | 1994-10-27 | 1999-11-16 | Thomas Jefferson University | TCL-1 gene and protein and related methods and compositions |
US7175995B1 (en) | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
US5695944A (en) | 1995-05-05 | 1997-12-09 | Thomas Jefferson University | Modulation of bcl-2 phosphorylation |
US5567586A (en) | 1995-05-18 | 1996-10-22 | Thomas Jefferson University | Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region |
US6242212B1 (en) | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
US5928884A (en) | 1996-02-09 | 1999-07-27 | Croce; Carlo M. | FHIT proteins and nucleic acids and methods based thereon |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
AU6659298A (en) | 1997-02-18 | 1998-09-08 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
EP0972083A1 (en) | 1997-04-04 | 2000-01-19 | THE TEXAS A&M UNIVERSITY SYSTEM | Noninvasive detection of colonic biomarkers using fecal messenger rna |
EP1098968A4 (en) | 1998-07-20 | 2002-01-02 | Univ Jefferson | NITRILASE APPROVALS |
WO2000005419A1 (en) | 1998-07-24 | 2000-02-03 | Yeda Research And Development Company Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
EP1165586A4 (en) | 1999-03-15 | 2003-05-28 | Univ Jefferson | TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS |
US7163801B2 (en) | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
SE0000522D0 (sv) * | 2000-02-17 | 2000-02-17 | Astrazeneca Ab | Mixing apparatus |
US6891031B2 (en) | 2000-02-18 | 2005-05-10 | The Regents Of The University Of California | Coordinate cytokine regulatory sequences |
WO2001068666A1 (en) | 2000-03-14 | 2001-09-20 | Thomas Jefferson University | Tcl1 enhances akt kinase activity and mediates its nuclear translocation |
ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
CA2406366A1 (en) | 2000-04-11 | 2001-10-18 | Thomas Jefferson University | Muir-torre-like syndrome infhit deficient mice |
WO2001087958A2 (en) | 2000-05-16 | 2001-11-22 | Thomas Jefferson University | CRYSTAL STRUCTURE OF WORM NitFhit REVEALS THAT A Nit TETRAMER BINDS TWO Fhit DIMERS |
US7060811B2 (en) | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
US20040033502A1 (en) | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
GB0128898D0 (en) | 2001-12-03 | 2002-01-23 | Biotech Res Ventures Pte Ltd | Materials and methods relating to the stabilization and activation of a tumour suppressor protein |
MXPA04008722A (es) | 2002-03-08 | 2005-07-13 | Eisai Co Ltd | Compuestos macrociclicos utiles como farmaceuticos. |
AU2003226279A1 (en) | 2002-04-08 | 2003-10-27 | Ciphergen Biosystems, Inc. | Serum biomarkers in hepatocellular carcinoma |
ATE446675T1 (de) | 2002-04-29 | 2009-11-15 | Univ Jefferson | Humane chronische lymphozytische leukämie im mausmodell durch gezielte expression von tcl1 |
US7217568B2 (en) | 2002-05-31 | 2007-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying and isolating stem cells and cancer stem cells |
US8119610B2 (en) | 2002-05-31 | 2012-02-21 | The Regents Of The University Of California | Method for efficient RNA interference in mammalian cells |
US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
US20050266443A1 (en) | 2002-10-11 | 2005-12-01 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
AU2003284083A1 (en) | 2002-10-11 | 2004-05-04 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
CN102304570B (zh) | 2002-11-13 | 2015-01-21 | 托马斯杰斐逊大学 | 用于癌症诊断和治疗的组合物和方法 |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2004071464A2 (en) | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
US7183384B2 (en) | 2003-03-06 | 2007-02-27 | A & G Pharmaceutical, Inc. | Monoclonal antibody 7H11 reactive with human cancer |
AU2003286741A1 (en) | 2003-05-02 | 2004-11-26 | Thomas Jefferson University | Methods and compositions for diagnosis and therapy of parkin-associated disorders |
US20050069918A1 (en) | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
BRPI0411526A (pt) | 2003-06-18 | 2006-08-01 | Genelux Corp | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
US20050037362A1 (en) | 2003-08-11 | 2005-02-17 | Eppendorf Array Technologies, S.A. | Detection and quantification of siRNA on microarrays |
US8412541B2 (en) | 2003-08-14 | 2013-04-02 | Edda Technology, Inc. | Method and system for intelligent qualitative and quantitative analysis for medical diagnosis |
US20050084883A1 (en) | 2003-08-25 | 2005-04-21 | The Johns Hopkins University School Of Medicine | Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis |
JP2007505634A (ja) | 2003-09-22 | 2007-03-15 | ロゼッタ インファーマティクス エルエルシー | Rna干渉を用いる合成致死スクリーニング |
WO2005028675A2 (en) | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc) |
US20050186589A1 (en) | 2003-11-07 | 2005-08-25 | University Of Massachusetts | Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi |
US20050164252A1 (en) | 2003-12-04 | 2005-07-28 | Yeung Wah Hin A. | Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell |
US8034548B2 (en) | 2003-12-19 | 2011-10-11 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies |
EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
EP1723162A4 (en) | 2004-02-13 | 2010-05-05 | Univ Rockefeller | ANTI-microRNA oligonucleotide molecules |
CA2558366A1 (en) | 2004-02-23 | 2005-09-01 | Erasmus Universiteit Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
CA2585525A1 (en) | 2004-04-20 | 2005-11-03 | Genaco Biomedical Products, Inc. | Method for detecting ncrna |
IL179285A (en) | 2004-05-14 | 2011-04-28 | Rosetta Genomics Ltd | Micrornas and uses thereof |
EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
US20060037088A1 (en) | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
EP1797183B1 (en) | 2004-09-02 | 2012-08-01 | Yale University | Regulation of oncogenes by micrornas |
US7592441B2 (en) | 2004-10-04 | 2009-09-22 | Rosetta Genomics Ltd | Liver cancer-related nucleic acids |
US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
FR2877350B1 (fr) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
CA2850323A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
AU2005316384B2 (en) | 2004-12-14 | 2012-02-09 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
DE602006016739D1 (de) | 2005-01-25 | 2010-10-21 | Rosetta Inpharmatics Llc | Verfahren zur quantifizierung kleiner rna-moleküle |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
GB2425311A (en) | 2005-04-15 | 2006-10-25 | Ist Superiore Sanita | Micro RNA against kit protein |
EP2631292A3 (en) | 2005-04-29 | 2013-11-20 | The Rockefeller University | Human microRNAs and methods for inhibiting same |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
US20070065844A1 (en) | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
US20060292616A1 (en) | 2005-06-23 | 2006-12-28 | U.S. Genomics, Inc. | Single molecule miRNA-based disease diagnostic methods |
EP1937845B1 (en) | 2005-08-01 | 2015-06-10 | The Ohio State University Research Foundation | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer |
US20070123482A1 (en) | 2005-08-10 | 2007-05-31 | Markus Stoffel | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
EP1937280B1 (en) | 2005-09-12 | 2014-08-27 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers |
CN101312740A (zh) | 2005-10-05 | 2008-11-26 | 俄亥俄州立大学研究基金会 | Wwox基因、包含该基因的载体和在癌症治疗中的用途 |
US7390792B2 (en) | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
US7943318B2 (en) | 2006-01-05 | 2011-05-17 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
EP2487253B1 (en) | 2006-01-05 | 2015-06-24 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
EP2591794A1 (en) | 2006-01-05 | 2013-05-15 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
US20090007281A1 (en) | 2006-01-13 | 2009-01-01 | Battelle Memorial Institute | Animal Model for Assessing Copd-Related Diseases |
EP1996731A2 (en) | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
WO2007112097A2 (en) | 2006-03-24 | 2007-10-04 | Children's Medical Center Corporation | Novel signature self renewal gene expression programs |
KR101407707B1 (ko) | 2006-04-03 | 2014-06-19 | 산타리스 팔마 에이/에스 | Anti-mirna 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물 |
WO2007127190A2 (en) | 2006-04-24 | 2007-11-08 | The Ohio State University Research Foundation | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
EP2455494B1 (en) | 2006-07-13 | 2013-12-18 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
US20080193943A1 (en) | 2006-09-05 | 2008-08-14 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
AU2007346101B2 (en) | 2006-09-19 | 2013-08-15 | The Ohio State University Research Foundation | TCL1 expression in chronic lymphocytic leukemia (CLL) regulated by miR-29 and miR-181 |
EP2487240B1 (en) | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008036776A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
JP2010504350A (ja) | 2006-09-19 | 2010-02-12 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、miR−200によって調節される遺伝子および経路 |
EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
US8293684B2 (en) | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
WO2008070082A2 (en) | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
WO2008073919A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
US20090092974A1 (en) | 2006-12-08 | 2009-04-09 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
AU2007333107A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
CA2671299A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
US20090175827A1 (en) | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
CN103555825B (zh) | 2007-01-31 | 2015-09-30 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
TWI367949B (en) | 2007-04-10 | 2012-07-11 | Univ Nat Taiwan | Predicting post-treatment survival in cancer patients with microrn |
AU2008248319B2 (en) | 2007-04-30 | 2013-09-05 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
US20090005336A1 (en) | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
US20090232893A1 (en) | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090131354A1 (en) | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
AU2008261951A1 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | miR-34 regulated genes and pathways as targets for therapeutic intervention |
JP5690588B2 (ja) | 2007-06-08 | 2015-03-25 | アメリカ合衆国 | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 |
CN101918424A (zh) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白 |
EP2808398A1 (en) | 2007-07-31 | 2014-12-03 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting DNMT3A and DNMT3B |
ES2627059T3 (es) | 2007-08-03 | 2017-07-26 | The Ohio State University Research Foundation | Regiones ultraconservadas que codifican ARNnc |
CA2696887C (en) | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
US20090061424A1 (en) | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
AU2008296022B2 (en) | 2007-09-06 | 2014-01-23 | The Ohio State University Research Foundation | MicroRNA signatures in human ovarian cancer |
JP5723156B2 (ja) | 2007-10-11 | 2015-05-27 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | 食道腺癌の診断及び治療のための方法及び組成物 |
JP2011504093A (ja) | 2007-10-26 | 2011-02-03 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 脆弱性ヒスチジン三連構造(fhit)相互作用を同定するための方法およびその使用 |
US20090123933A1 (en) | 2007-11-12 | 2009-05-14 | Wake Forest University Health Sciences | Microrna biomarkers in lupus |
US8575121B2 (en) | 2007-11-12 | 2013-11-05 | The United States of America as represented by the Secetary of the Department of Health and Human Services | Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
US20100323357A1 (en) | 2007-11-30 | 2010-12-23 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
WO2009086156A2 (en) | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
AU2009212543B2 (en) | 2008-02-01 | 2015-07-09 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
WO2009100430A2 (en) | 2008-02-08 | 2009-08-13 | Asuragen, Inc | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
JP2011516033A (ja) | 2008-02-28 | 2011-05-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 急性骨髄性性白血病(aml)における細胞遺伝学および予後と関連するマイクロrnaシグネチャーおよびその使用 |
JP5662166B2 (ja) | 2008-02-28 | 2015-01-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | 胃癌の診断、予後診断及び治療のためのマイクロrnaに基づいた方法及び組成物 |
JP2011517932A (ja) | 2008-02-28 | 2011-06-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | ヒト慢性リンパ球性白血病(ccl)と関連するマイクロrnaシグネチャーおよびその使用 |
EP2260109A4 (en) | 2008-02-28 | 2011-06-08 | Univ Ohio State Res Found | METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR DIAGNOSING, PROGNOSING AND TREATING PROSTATE-RELATED DISORDERS |
EP2268832A2 (en) | 2008-03-06 | 2011-01-05 | Asuragen, INC. | Microrna markers for recurrence of colorectal cancer |
WO2009154835A2 (en) | 2008-03-26 | 2009-12-23 | Asuragen, Inc. | Compositions and methods related to mir-16 and therapy of prostate cancer |
EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
CN102112110A (zh) | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | 用于RNAi试剂体内递送的新型组合物 |
US9125923B2 (en) | 2008-06-11 | 2015-09-08 | The Ohio State University | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy |
EP2323677A4 (en) | 2008-08-12 | 2013-01-09 | Univ Ohio State Res Found | MICRO-RNA BASED COMPOSITIONS AND METHODS OF DIAGNOSIS, FORECAST AND TREATMENT OF MULTIPLE MYELOMA |
US20110311555A1 (en) | 2008-11-21 | 2011-12-22 | The Ohio State University | Tc11 as a Transcriptional Regulator |
US20110275534A1 (en) | 2008-12-05 | 2011-11-10 | The Ohio State University | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform |
EP2401405A4 (en) | 2009-02-26 | 2013-10-16 | Univ Ohio State Res Found | MICROARN IN NON-SMOKERS AND METHODS AND RELATED MATERIALS |
-
2007
- 2007-01-03 US US12/160,034 patent/US7943318B2/en active Active
- 2007-01-03 ES ES12165748.0T patent/ES2536438T3/es active Active
- 2007-01-03 EP EP07717734.3A patent/EP1978986B1/en not_active Not-in-force
- 2007-01-03 AU AU2007205234A patent/AU2007205234B2/en not_active Ceased
- 2007-01-03 JP JP2008549549A patent/JP5451077B2/ja not_active Expired - Fee Related
- 2007-01-03 EP EP12165740.7A patent/EP2514434B1/en not_active Not-in-force
- 2007-01-03 EP EP12165734.0A patent/EP2514433B1/en not_active Not-in-force
- 2007-01-03 ES ES07717734T patent/ES2429404T3/es active Active
- 2007-01-03 EP EP12165748.0A patent/EP2502630B1/en not_active Not-in-force
- 2007-01-03 WO PCT/US2007/000103 patent/WO2007081720A2/en active Application Filing
- 2007-01-03 CA CA002633674A patent/CA2633674A1/en not_active Abandoned
- 2007-01-03 CN CN2007800067508A patent/CN101400361B/zh not_active Expired - Fee Related
- 2007-01-03 ES ES12165740.7T patent/ES2553442T3/es active Active
- 2007-01-03 ES ES12165734.0T patent/ES2554531T3/es active Active
- 2007-01-03 CN CN201210312507.1A patent/CN102943108B/zh not_active Expired - Fee Related
- 2007-01-03 CN CN201410210166.6A patent/CN103993082B/zh not_active Expired - Fee Related
-
2011
- 2011-03-30 US US13/075,820 patent/US8361710B2/en not_active Expired - Fee Related
- 2011-03-30 US US13/075,828 patent/US8377637B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2536438T3 (es) | Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón | |
ES2545360T3 (es) | Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos | |
CN101384273B (zh) | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 | |
JP2008519606A5 (es) | ||
AU2014203454B2 (en) | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
AU2013245505A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |